The FDA’s Arthritis Advisory Committee voted unanimously in support of the biosimilar, from Novartis’ Sandoz generics and biosimilars unit, for all five indications of the reference product.

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

The nation has greenlit Omlyclo — a biosimilar of, or lower-cost alternative to Novartis's Xolair — to treat chronic idiopathic urticaria (CIU), chronic rhinosinusitis with nasal polyps ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will ...